Corcept Therapeutics (CORT) Non-Current Assets (2010 - 2026)

Corcept Therapeutics has disclosed Non-Current Assets across 17 years of filings, most recently posting $388.8 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $388.8 million, down 4.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 10.68% YoY), and the FY2025 annual result was $351.2 million, down 4.81% from the prior year.
• Non-Current Assets came in at $388.8 million for Q1 2026 at Corcept Therapeutics, up from $351.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $408.0 million in Q1 2025 to a low of $77.3 million in Q2 2022.
• The 5-year median for Non-Current Assets is $162.5 million (2023), against an average of $212.1 million.
• Across the five-year window, Non-Current Assets tumbled 55.94% in 2022 and soared 167.39% in 2025, its largest moves.
• Corcept Therapeutics' Non-Current Assets stood at $84.2 million in 2022, then soared by 93.5% to $162.9 million in 2023, then jumped by 126.52% to $369.0 million in 2024, then slipped by 4.81% to $351.2 million in 2025, then gained by 10.72% to $388.8 million in 2026.
• The last three Non-Current Assets figures came in at $388.8 million (Q1 2026), $351.2 million (Q4 2025), and $282.5 million (Q3 2025), per Business Quant data.